market MyDay We hydrogel excited strength everyone a momentum. silicone took portfolio note We this on started Thank our Biofinity. to positive contact in our led fiscal the in call. conference are we year you, Cooper's by lens share Kim, and and first with welcome, quarter and off about
XX%. and continued and management portfolio fertility moving very posted strong cash growing flow forward. a earnings we CooperSurgical quarter million, XX% including myopia $X expect XX% with growing both and delivered continued robust With businesses and PARAGARD strong Our to outperforming, MiSight strengthen, to performance
the challenges, per currency and on all and revenues X%. $XXX a were continuing with $XXX CooperSurgical COVID posted share quarter X% we revenues million, CooperVision of reporting earnings revenues of constant up Regarding million, up $XXX with Non-GAAP percentages $X.XX. consolidated of basis, even million
our in led we CooperVision, By hydrogel Biofinity along for by down Biofinity silicone in continued nice growth strength COVID-related from restrictions. was general silicones, both saw torics multifocals. though, through the in our strength silicones that portfolio bodes so strength daily daily well Americas countries For in including franchise, Biofinity and managing in and X% clariti X% several We grew geography, and stringent EMEA with MyDay. and growth see as and future. did daily the our
MyDay, current Pac positioned with growing are in up continue X% in and Japan. Asia product led driving to was especially expectations, well exceeded future and we strength sales share taking and launches Overall, by momentum.
additional some numbers. to quarterly Moving
dailies with around growing. daily that both X% especially clariti strength MyDay as rolling and hydrogel silicone the was noted product there and hydrogels continue need Our be to $X.X health as that of global and trends will drive up. now right wellness market older adoption is sales believe grew are silicones MyDay Particular in continue the as that traded out Overall, toric in annual world. we we billion MyDay still leading and
differentiate year offering multifocal as fatigue alleviate And and is a excessive is Optics product multifocal. in before, of I've our eye but part portfolio. mentioned launched a to Energys In extensive to are with products reminder, well. truly a last noted unique was innovative and that our these uses strength Biofinity extremely products today's FRP Biofinity has ability time. doing Biofinity this made-to-order we world, X% that from well product Moving our perform screen help is and the This and Energys Digital that. business. our and toric to grew of lens seeing Biofinity unique Zone toric
launches, product successful we doing launch in We and now shortly. addition regulatory And market. to that incredibly a in Japan, active. our will curve Regarding that's launch MyDay have of second remain we be approval that base clariti in sphere to ongoing for
We and are world. also launch in many toric MyDay continuing around to sphere markets relaunch the and other
toric the We out for are and in toric continuing ranges extended we Biofinity shortly, Europe launching are Biofinity. rollout of multifocal, rolling including clariti and
XX% and Ortho including over X,XXX of GP in million last Specialists our the we active With of to $X grew now K over grew around we K forward. acquisition with wearing XX,XXX grew Ortho expect respect which of August to accelerating. busy Within the lastly, U.S. kids $X and to And the lens, lenses, our XX% are is myopia MiSight pipeline revenue from have Additionally, to million. our our from management quarter MiSight, very $XX world incredibly momentum XX%, and we going and is million MiSight for of strong remain portfolio this, year. including the
Our launch well, markets, go we we months. as Korea, in launching similar success South next such to will new and few activity where be continues extremely expect in the
U.S. large Popular made in retailers stores. associations making to are and several We've with care. several moved schools retailer training as to optometry with From received for their Comparing contact average awards age MiSight from exceeding our this MiSight sales perspective, Contact look with the This is in a a a for discussions exciting and bringing year. supporting XX also curriculums. many new we wear universities, supports several even progress myopia data, trending which students is advancements recognize of are management a standard Science multiple year and much and professional including advancements it's extremely made or and myopia shows of training fantastic. fiscal all next of positive into regular million XX adding if a age, education we age average and and phase the lens fitting helping large contact are Spectrum at now million MiSight we great reaching this courses get and over the wear And of younger. XX test the their management of at regarding XX kids with also roughly old Lens remains to have into buying younger We years new sign, groups we of recently, a one XX goal
reduce our the expertise spectacles Moving SightGlass and to want of commercialization spectacles. joint of spectacles our progression to acquisition partnership developed I global Vision, innovative to Vision leverage EssilorLuxottica our these myopia leadership world. in with around on venture the myopia management in and shared our recent children to touch accelerate and of will EssilorLuxottica. management SightGlass the has myopia with
we our is will in We we a working global a regulatory of having the marketplace. the as pediatric technology and we follow More be and developing entire to await is opportunity. will partner market game changer. requirements the The vision management, is pediatric its compliment JV wrap the an in this in data, working progress. at on of which are contact certain has next accelerate to through clinical myopia growth lenses, the we started SightGlass in been forefront product great extremely like two-year exciting now continue typical up only management couple the To are a of months. portfolio exciting growth EssilorLuxottica but on the making to existing the This plans out great markets, FDA-approved launch infancy, of exciting opportunity with myopia as form and MiSight
offers on such in global continuing health R&D and are programs detachment, such visual with retinal immediate and later as a to and driving life, myopia keep We patients, sales benefits, long-term regulatory basis. eye approvals the to adoption glaucoma. risk the serious in of addressing and as invest marketing reducing progression along new of many pediatric correction launches, disease in Proactively cataracts
optometry activity. involved definitely expect along retail benefit effort eye professionals foot increasing the supporting us why traffic add is especially the To staffing Vision, this strongly important will better attendance of at me let of So In and so it's that outlets, vaccines offices. and our given the conclude rollout and on getting care capacity and are we continuing nature this near-term, service malls, better with consumer business. many
strong our is myopic that's our the a a trend and back-to-school more industry On continuing in and with also macro world time very season currently growth in-person increase roughly by expected as XXXX. world. returns silicones, and basis, torics the improving and of the a on XX% trend multifocals, third drivers likely spending this are people strong a around that We of bright has to remain geographic daily longer-term growth expansion to estimated expect shift electronic learning one with It's Combining future. devices. to
for position strong and activity, For long-term with data robust puts us portfolio, product growth. management CooperVision, a our launch in great momentum product new fit sustainable active myopia
revenues to and right and were with now the we quarter throughout CooperSurgical. excited state Revenues team I'm led around XX% year-over-year a grew with a of We and leadership her looks strength Starting $XX took bright. about had world the and to fantastic really extremely the by our seen Overall rebounded future fertility. of Holly under and $XXX product up million strong million, X% the portfolio. healthy PARAGARD Moving share. very CooperSurgical as markets fertility.
for We our in are share with accounts. are taking future well gains positioned and we traction key improving
of spectrum business which the product our full One the fertility of needs clinics of products. broad pharma outside portfolio is covers our strengths essentially fertility of
growth trends on Within taking the and well are were and management X% building and the to better RFID products In are activity. than in incubators driven RI that growth COVID done and are lab-based trends market in I India remains fertility expected has such relationships negatively we PARAGARD trends, meantime, surgical ranging we have we genetic activity world as strong, great to the seeing in our significantly the the growth. testing. consumable has as we is Witness, from market but office still and XX%. we and still unit, the definitely positive drive We extremely by to continue. wellness pipettes, cross-selling larger quarter, macro areas a PARAGARD’s up important capitalize to with that we are in positive by this flow led pickup performed a job of around resulted patient impacting countries media solid expect are like and positioned growth patient Overall, a hampered, our discussed share and system these U.S. clinics long-term workstations to and health some last equipment From like of seeing perspective, market
and the fantastic As of U.S. on needs XXX% a product IUD the a offers only control the option alternative. interests women market, healthy birth hormone-free addresses that the for looking long-lasting
including bullish deferred elective seen quarter, device posting continue rescheduled, believe patented and EndoSee sales our the now, Several very direct surgical PARAGARD in our improved. closure system are and focus skin year. solid we procedures Advance, on of we uterine our endometrium; manipulators. Elsewhere, of medical this will We evaluation steadily of portfolio our right have visualization growth INSORB, products grew for device and our
Before governance. further it to turn on close let I enhance and environmental mentioning responsibility matters, good over to our corporate focus our strong efforts Brian, by me
out passion with or the of very connect. to great past the made interest assessment progress please work have over call And to anyone reach things ESG and lot just materiality happening ESG a my turn have focused the questions on I'll this that, in today. and and and commitment an to our has We ensure If type over exciting of years, strong. remains right Brian. several areas efforts, completed we We any stay we let's